Bioventus Inc.
HealthcareNASDAQ:BVS · NASDAQ Global Select
-$0.17 today
Vol 0.44M · Avg 0.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.3%
avg -14.1%
ROIC
10.8%
avg -0.1%
ROA
3.3%
avg -3.2%
Analysis
ROE is currently the strongest return metric at 12.3% versus its period average of -14.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Claypoole | President, Chief Executive Officer & Director | $1.65M | — | 54 | $309,000.00 | 0.46% |
Mark Singleton | Senior Vice President & Chief Financial Officer | $833,819.00 | — | 57 | $182,981.00 | 0.27% |
Anthony D'Adamio | Senior Vice President, General Counsel & Corporate Secretary | $713,659.00 | — | 65 | $9,925.00 | 0.01% |
Dave Venner | Senior Vice President & GM of Surgical | — | — | — | — | — |
Helen Leupold | Senior Vice President & Chief Human Resources Officer | — | — | — | — | — |
Katrina J. Church | Senior Vice President & Chief Compliance Officer | — | — | 64 | $4,300.00 | <0.01% |
David Crawford | Vice President of Investor Relations & Treasurer | — | — | — | $2,700.00 | <0.01% |
Mike Crowe | Senior Vice President of Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$312,351.89
Net Sentiment
$312,351.89
Net selling
Most Active
McMurry-Heath Michelle
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $312,351.89 over the last 12 months. That adds up to net selling of $312,351.89. McMurry-Heath Michelle was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +6.3% | +8.0% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | +1005.5% | N/A1 analysts |
Analysis
Recent growth has been strongest in EBIT at +1005.5% over three years. Forward estimates point to Revenue at +8.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Surmodics, Inc.
SRDX
$614.51M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Semler Scientific, Inc.
SMLR
$310.75M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
Who manages BVS?
Bioventus Inc. (BVS) lists 8 active executives. The top listed executive is Anthony D'Adamio, Senior Vice President, General Counsel & Corporate Secretary.
Are BVS insiders buying or selling?
Recent insider activity shows net buying of $5.91M.
Explore More
Continue the stock analysis
Jump to another research area for this company.